Next Article in Journal
Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape
Next Article in Special Issue
Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response
Previous Article in Journal
Anthocyanidins Inhibit Growth and Chemosensitize Triple-Negative Breast Cancer via the NF-κB Signaling Pathway
Previous Article in Special Issue
Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study
Article

Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients

1
Department of Radiation Oncology, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany
2
Diagnostisch Therapeutisches Zentrum (DTZ), 10243 Berlin, Germany
3
Department of Radiology, University Hospital, Ludwig Maximilian University, 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Jan B. Vermorken and Petr Szturz
Cancers 2021, 13(24), 6250; https://doi.org/10.3390/cancers13246250
Received: 2 December 2021 / Accepted: 10 December 2021 / Published: 13 December 2021
(This article belongs to the Special Issue Oligometastatic Disease)
Local ablative treatments have emerged as a promising treatment strategy for patients with oligometastatic disease. Interstitial brachytherapy (iBT) is one of the locally ablative treatment options for unresectable liver metastases in oligometastatic disease. We report the feasibility and oncologic outcome of 141 iBT treatments of 244 oligometastatic liver metastases performed in patients with limited tumor burdens in a high-volume center. iBT was feasible, safe and effective in the treatment of oligometastatic liver metastases with good local control rates and low toxicity. Histology and total tumor volume had an impact on local control rates.
Local ablative treatments have emerged as a promising treatment strategy for patients with oligometastatic disease. Among others, interstitial brachytherapy (iBT) is an upcoming treatment option for unresectable liver metastases. We report the feasibility and oncologic outcome of iBT of oligometastatic liver metastases performed in patients with limited tumor burdens in a high-volume center. Patients undergoing iBT between August 2017and March 2019 were included. A retrospective analysis of patient outcomes and treatment complications was performed. Patients treated for metastatic colorectal carcinoma (CRC) were compared to other histologies. A total of 141 iBT procedures were performed in 106 patients (male:52; female:54) and 244 liver metastases. Overall, 51% (54/106) of patients had a diagnosis of metastatic CRC. The median follow-up was 9 months, and overall survival (OS) was 92.3% at 6 months and 76.3% at 12 months. Local-relapse-free survival (LRFS) was 88.4% at 6 months and 71.5% at 12 months, with a significant difference between patients with CRC (84.1% and 50.6%) versus other histologies (92.4% and 92.4%, p < 0.001). A sub-group analysis showed a significant advantage in patients with CRC receiving a minimal dose (D100) of 20 Gy to the planning target volume. Treatments of smaller total liver-tumor volumes (<18 ccm) resulted in better LRFS rates. iBT is a safe and effective treatment approach for oligometastatic liver disease. A higher treatment dose is needed for patients with CRC. Moreover, lower metastatic burdens may be favorable for LRFS. Prospective studies are needed to assess the role of iBT in the oligometastatic setting as an alternative to other local ablative treatment approaches in patients with liver metastases. View Full-Text
Keywords: liver; metastases; brachytherapy; radiotherapy; local control; survival; outcome liver; metastases; brachytherapy; radiotherapy; local control; survival; outcome
Show Figures

Figure 1

MDPI and ACS Style

Walter, F.; Rottler, M.; Nierer, L.; Landry, G.; Well, J.; Rogowski, P.; Mohnike, K.; Seidensticker, M.; Ricke, J.; Belka, C.; Corradini, S. Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers 2021, 13, 6250. https://doi.org/10.3390/cancers13246250

AMA Style

Walter F, Rottler M, Nierer L, Landry G, Well J, Rogowski P, Mohnike K, Seidensticker M, Ricke J, Belka C, Corradini S. Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers. 2021; 13(24):6250. https://doi.org/10.3390/cancers13246250

Chicago/Turabian Style

Walter, Franziska, Maya Rottler, Lukas Nierer, Guillaume Landry, Justus Well, Paul Rogowski, Konrad Mohnike, Max Seidensticker, Jens Ricke, Claus Belka, and Stefanie Corradini. 2021. "Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients" Cancers 13, no. 24: 6250. https://doi.org/10.3390/cancers13246250

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop